Vcare 2023 Annual Review
Published Time:
2024-02-07 17:49
Source:
I. Important Progress in Innovative Drug R&D
① Submitted NDA to US FDA for anti-platelet drug Vicagrel: If approved, it may benefit ~27.6M US patients with coronary heart disease/stroke.
② Completed 1st patient enrollment in China’s Phase II trial for anti-resistant TRK inhibitor VC004: Phase I data showed ORR of 80%-90% in NTRK fusion+ solid tumors and DOR up to 24 months.
③ Completed Phase II enrollment for 2nd-gen selective JAK1 inhibitor VC005 in ankylosing spondylitis: Preliminary blinded analysis showed favorable efficacy/safety.
Additionally: VC004 gel approved for clinical trials; VC005 gel initiated China Phase I for atopic dermatitis; Multiple preclinical projects advanced in cardio-cerebrovascular, oncology, and autoimmune fields.
II. CRO/CDMO Service Revenue
2023 external service revenue: ~RMB 400 million (+25.5% YoY); New contracts: >RMB 550 million (+16.1% YoY).
III. Production Base Development
① Tianshu Pharmaceutical Phase I facility operational: 240+ employees; Robust quality system established; Passed 30+ audits by global clients/regulators; Monthly output exceeded RMB 10M since July trial production, reaching RMB 35M in December.
② Obtained Drug Manufacturing Certificate: enabling compliant API and innovative drug CDMO production.
IV. Corporate Financing
Closed Series C financing >RMB 450 million amid market downturn: Named among 2023 Top 10 Pharma Financing Projects in China; Total financing 2021-2023: ~RMB 1B; Valuation >RMB 3B.
V. Employee Care
① Organized 6 cultural events
② Held 12 Happy Hour activities
③ Completed 60+ promotions & 80+ internal trainings
④ 60+ employees received 3rd equity incentive
VI. Awards & Honors
Jiangsu Vcare Honored As: Jiangsu Provincial Enterprise Technology Center; Jiangsu Science & Technology Second Prize
Nanjing Vcare Honored As: Top 20 CRO Enterprises in China; High-Tech Enterprise; Nanjing Innovative SME
Related News
28
2025
/
04
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced the successful enrollment of the first participant in its Phase II clinical trial for VC005 topical gel, a self-developed next-generation highly selective JAK1 inhibitor, for the treatment of mild-to-moderate atopic dermatitis (AD). The trial aims to evaluate the efficacy of VC005 gel in adult patients with mild-to-moderate AD, providing a critical data for dose selection in future clinical studies and further assesses the drug's safety profile.
View Details
11
2025
/
04
Recently, following joint review by Nanjing Jiangbei New Area Sci-Tech Bureau and Nanjing Municipal Science and Technology Bureau, the"Nanjing Key Laboratory for Artificial Intelligence (AI) Drug Design"established byJiangsu Vcare Pharmatech Co., Ltd.(Jiangsu Vcare) was approved as a 2025 Nanjing Key Laboratory. This marks authoritative recognition of Jiangsu Vcare’s scientific capabilities, with the Lab having achieved significant progress in drug design and molecular discovery.
View Details
26
2025
/
03
Jiangsu Vcare Launches Phase II Trial for VC005 Topical Gel in Mild-to-Moderate Atopic Dermatitis
On March 26, 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) officially launched the Phase II clinical trial for its self-developed, highly selective JAK1 inhibitor VC005 gel for the topical treatment of mild-to-moderate atopic dermatitis (AD). The completed Phase I clinical study of VC005 gel demonstrated excellent safety and significant efficacy.
View Details
27
2025
/
01
Jiangsu Vcare Honored As: National-Level Specialized, Refined, Unique, and Innovative "Little Giant" Enterprises; Top 100 China Pharma Innovation Seed Enterprises; Jiangsu Listed Sci-Tech Enterprise Cultivation Program; Jiangsu Chemical Innovative Drug Engineering Research Center; Top 500 China Hidden Unicorn Enterprises
View Details
26
2025
/
01
In January 2025, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that its self-developed next-generation anti-resistant TRK inhibitor VC004 capsule has officially entered the domestic NDA preparation phase, initiating pre-NDA communications with regulatory authorities. Marking this milestone, Jiangsu Vcare has joined the top tier of domestic self-developed drugs targeting this pathway at remarkable speed.
View Details
22
2025
/
01
Jiangsu Vcare Secures Nearly CNY 200 Million in Series C+ Financing
Recently, Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) closed its Series C+ financing round, raising nearly CNY 200 million. The round was jointly invested by Xinghe Venture Capital, Jinlong Investment, SDIC Capital, and Yangtze River Industry Group. The proceeds will accelerate clinical advancement of Jiangsu Vcare’s innovative drug pipelines, strengthen its integrated CRO/CDMO service ecosystem, enhance independent innovation capabilities, and advance strategic initiatives in synthetic biology and green chemistry. This brings Jiangsu Vcare’s total equity financing to over CNY 1 billion, demonstrating sustained capital market confidence.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
Powerby：www.300.cn nanjing.300.cn